FDA Approves New Daily Cholesterol Pill Shown to Lower LDL by Up to 60%

1-Minute Brief

The approval introduces a new treatment option for patients who need additional cholesterol reduction beyond what statins provide.

Key Facts

• The FDA has approved a new daily cholesterol-lowering pill called Lipfendra.
• Clinical trials showed the new pill can lower cholesterol levels far below what can be achieved with statins.
• Lipfendra is the first once-daily oral PCSK9 inhibitor available for cholesterol management.
• When combined with statins, Lipfendra reduced LDL cholesterol by approximately 56% to 60%.
• The pill works differently from statins, offering an alternative mechanism for lowering cholesterol.

What Happened

The FDA approved Lipfendra, a new daily oral cholesterol-lowering medication, following clinical trials that demonstrated significant reductions in LDL cholesterol, especially when used alongside statins.

Why It Matters

This approval provides an alternative for patients who do not achieve sufficient cholesterol reduction with statins alone or cannot tolerate them, potentially improving cardiovascular risk management.

What's Next

Healthcare providers may begin prescribing Lipfendra to eligible patients. Further monitoring and studies may assess long-term outcomes and broader patient response.